Seeking Alpha
16 Jul 2026, 14:25 UTC · 13w ago
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Impact · against what's priced in
Abivax is positioned for significant valuation growth following robust Phase 3 clinical remission data (50.8%–51.3%) for obefazimod and a substantial capital injection. The $920M raise effectively removes financing risk and enables a standalone commercialization strategy through 2029.
- ABVX+0.80
No priced-in read yet
- In context
The clinical remission rates of 50.8%–51.3% at week 44 and the $920M capital raise provide a concrete path to regulatory approval and commercial execution.
Read from the article alone
Top 1 mover · tap to explore
